Download PDF
Hamostaseologie 2020; 40(02): 174-183
DOI: 10.1055/a-1113-0689
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Prevention of Pregnancy Complications in Antiphospholipid Syndrome

Andreas Czwalinna
1   amedes MVZ wagnerstibbe für Laboratoriumsmedizin, Hämostaseologie, Humangenetik und Mikrobiologie, Hannover, Germany
,
Frauke Bergmann
1   amedes MVZ wagnerstibbe für Laboratoriumsmedizin, Hämostaseologie, Humangenetik und Mikrobiologie, Hannover, Germany
› Author Affiliations
Further Information

Publication History

08 November 2019

23 January 2020

Publication Date:
26 May 2020 (online)

Also available at
   Permissions and Reprints

Abstract

Despite a lot of research on antiphospholipid antibodies (aPL), standardization of test systems, and better definition of its clinical symptoms, the pathomechanism of this acquired autoimmune disease is not yet fully explained. Progress in treatment increased the live birth rate in 70 to 80% of women suffering from obstetric antiphospholipid syndrome (OAPS). However, still 20 to 30% will develop adverse pregnancy outcome. Lack of awareness of this disorder as the cause for pregnancy complications is very harmful to mothers and to their newborns. Complications can be avoided or minimized by proper treatment. The aim of this article is to increase the awareness of gynecologists and medical personal for OAPS.

Zusammenfassung

Trotz erheblicher Forschungsaktivität auf dem Gebiet Antiphospholipid-Antikörper (aPL) über drei Dekaden, verbesserter Standardisierung der Testsysteme und exakter Klassifikation der klinischen Kriterien als Basis aktueller Studien, ist der Pathomechanismus dieser erworbenen Autoimmunerkrankung noch nicht völlig aufgeklärt. Durch Fortschritte in der Behandlung betroffener Frauen ist die Lebendgeburtenrate bei Frauen mit gynäkologischem (obstetrical) Antiphospholipid-Syndrom (OAPS) auf 70–80% gestiegen. Trotzdem treten in 20–30% der Schwangerschaften schwere Schwangerschaftskomplikationen auf. Das fehlende Wissen um dieses Krankheitsbild als Ursache von Schwangerschaftskomplikationen bzw. das Nichterkennen der Symptome ist für betroffene Frauen und ihr Neugeborenes gefährlich. Komplikationen wären durch Prophylaxemaßnahmen vermeidbar bzw. zu reduzieren. Ziel dieser Übersichtsarbeit ist es, das Wissen um diese Erkrankung bei Gynäkologen und medizinischem Fachpersonal zu vertiefen und die Aufmerksamkeit für dieses Krankheitsbild zu schärfen.

Keywords

antiphospholipid syndrome - antiphospholipid antibodies - aPL profile - adverse pregnancy outcome - recurrent fetal loss

Schlüsselwörter

Antiphospholipid-syndrom - Antiphospholipid-antikörper - aPL-Profil - Schwangerschaftskomplikationen - Wiederholte Spontanaborte (WSA)
 

  • References

  • 1 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
    CrossrefPubMedSearch in Google Scholar
  • 2 McDonnell T, Wincup C, Buchholz I. , et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: more than just APS. Blood Rev 2020; 39: 100610
    CrossrefPubMedSearch in Google Scholar
  • 3 Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93 (06) 1147-1152
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 de Jesus GR, Agmon-Levin N, Andrade CA. , et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014; 13 (08) 795-813
    CrossrefPubMedSearch in Google Scholar
  • 5 Pengo V, Ruffatti A, Legnani C. , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
    PubMedSearch in Google Scholar
  • 6 Gris JC, Bouvier S, Molinari N. , et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119 (11) 2624-2632
    CrossrefPubMedSearch in Google Scholar
  • 7 Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand 1975; 197 (03) 153-159
    PubMedSearch in Google Scholar
  • 8 Hughes GR, Harris EN, Gharavi AE. The syndrome of thrombosis, abortion, and neurological disease. Contrib Nephrol 1984; 43: 9-11
    PubMedSearch in Google Scholar
  • 9 Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26 (05) 324-326
    CrossrefPubMedSearch in Google Scholar
  • 10 Lockshin MD, Druzin ML, Goei S. , et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313 (03) 152-156
    CrossrefPubMedSearch in Google Scholar
  • 11 Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313 (21) 1322-1326
    CrossrefPubMedSearch in Google Scholar
  • 12 Radin M, Sciascia S. Infodemiology of systemic lupus erythematous using Google Trends. Lupus 2017; 26 (08) 886-889
    CrossrefPubMedSearch in Google Scholar
  • 13 Tripodi A, Chantarangkul V, Cini M. , et al. Variability of cut-off values for the detection of lupus anticoagulants: results of an international multicenter multiplatform study. J Thromb Haemost 2017; 15 (06) 1180-1190
    CrossrefPubMedSearch in Google Scholar
  • 14 Devreese KM. Standardization of antiphospholipid antibody assays. Where do we stand?. Lupus 2012; 21 (07) 718-721
    CrossrefPubMedSearch in Google Scholar
  • 15 Durcan L, Petri M. Epidemiology of the antiphospholipid syndrome. In: Cervera R, Espinosa G, Khamashta M. , eds. Handbook of Systemic Autoimmune Diseases. Vol. 12. Amsterdam: Elsevier; 2017: 17-30
    Search in Google Scholar
  • 16 Duarte-García A, Pham MM, Crowson CS. , et al. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheumatol 2019; 71 (09) 1545-1552
    Search in Google Scholar
  • 17 Meroni PL, Mari D, Monti D. , et al. Anti-beta 2 glycoprotein I antibodies in centenarians. Exp Gerontol 2004; 39 (10) 1459-1465
    CrossrefPubMedSearch in Google Scholar
  • 18 Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52 (09) 2774-2782
    CrossrefPubMedSearch in Google Scholar
  • 19 Taraborelli M, Lazzaroni MG, Martinazzi N. , et al. The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus. Reumatismo 2016; 68 (03) 137-143
    CrossrefPubMedSearch in Google Scholar
  • 20 Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61 (01) 29-36
    PubMedSearch in Google Scholar
  • 21 Cervera R, Serrano R, Pons-Estel GJ. , et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74 (06) 1011-1018
    PubMedSearch in Google Scholar
  • 22 Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65 (11) 1869-1873
    PubMedSearch in Google Scholar
  • 23 Bowman ZS, Wünsche V, Porter TF, Silver RM, Branch DW. Prevalence of antiphospholipid antibodies and risk of subsequent adverse obstetric outcomes in women with prior pregnancy loss. J Reprod Immunol 2015; 107: 59-63
    CrossrefPubMedSearch in Google Scholar
  • 24 Mekinian A, Loire-Berson P, Nicaise-Roland P. , et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol 2012; 94 (02) 222-226
    CrossrefPubMedSearch in Google Scholar
  • 25 Simchen MJ, Dulitzki M, Rofe G. , et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 2011; 90 (12) 1428-1433
    CrossrefPubMedSearch in Google Scholar
  • 26 Devreese KMJ, Ortel TL, Pengo V, de Laat B. ; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (04) 809-813
    CrossrefPubMedSearch in Google Scholar
  • 27 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014; 111 (02) 354-364
    Thieme ConnectPubMedSearch in Google Scholar
  • 28 Pierangeli SS, Chen PP, Raschi E. , et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34 (03) 236-250
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Schreiber K, Sciascia S, de Groot PG. , et al. Antiphospholipid syndrome. Nat Rev Dis Primers 2018; 4: 17103
    CrossrefPubMedSearch in Google Scholar
  • 30 de Laat B, Pengo V, Pabinger I. , et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7 (11) 1767-1773
    CrossrefPubMedSearch in Google Scholar
  • 31 Pengo V, Ruffatti A, Tonello M. , et al. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015; 13 (05) 782-787
    CrossrefPubMedSearch in Google Scholar
  • 32 Chighizola CB, Pregnolato F, Andreoli L. , et al. Beyond thrombosis: anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. J Autoimmun 2018; 90: 76-83
    CrossrefPubMedSearch in Google Scholar
  • 33 Abrahams VM, Chamley LW, Salmon JE. Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation. Arthritis Rheumatol 2017; 69 (09) 1710-1721
    CrossrefPubMedSearch in Google Scholar
  • 34 Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018; 378 (21) 2010-2021
    CrossrefPubMedSearch in Google Scholar
  • 35 Girardi G, Berman J, Redecha P. , et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112 (11) 1644-1654
    CrossrefPubMedSearch in Google Scholar
  • 36 Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10 (11) 1222-1226
    CrossrefPubMedSearch in Google Scholar
  • 37 Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196 (02) 167.e1-167.e5
    CrossrefPubMedSearch in Google Scholar
  • 38 Tedesco F, Borghi MO, Gerosa M. , et al. Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications. Front Immunol 2018; 9: 1388
    CrossrefPubMedSearch in Google Scholar
  • 39 Rovere-Querini P, Canti V, Erra R. , et al. Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 2018; 97 (40) e12584
    PubMedSearch in Google Scholar
  • 40 Chighizola CB, Andreoli L, Gerosa M, Tincani A, Ruffatti A, Meroni PL. The treatment of anti-phospholipid syndrome: a comprehensive clinical approach. J Autoimmun 2018; 90: 1-27
    CrossrefPubMedSearch in Google Scholar
  • 41 Stefanovic V. The extended use of eculizumab in pregnancy and complement activation-associated diseases affecting maternal, fetal and neonatal kidneys-the future is now?. J Clin Med 2019; 8 (03) E407
    CrossrefPubMedSearch in Google Scholar
  • 42 Lackner KJ, Müller-Calleja N. Cofactor-independent antiphospholipid antibodies: implications for pathogenesis, diagnosis, and treatment of antiphospholipid syndrome. Hamostaseologie 2019; 39 (02) 188-194
    Thieme ConnectPubMedSearch in Google Scholar
  • 43 Regan L, Backos M, Rai R. . The investigation and treatment of couples with recurrent firsttrimester and second-trimester miscarriage [Green-top Guideline No. 17]. Royal College of Obsetrican & Gynaecologists. 2011; 1-18 . Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf . Accessed February 17, 2020
    PubMedSearch in Google Scholar
  • 44 Rai RS, Regan L, Clifford K. , et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10 (08) 2001-2005
    CrossrefPubMedSearch in Google Scholar
  • 45 Cohn DM, Goddijn M, Middeldorp S, Korevaar JC, Dawood F, Farquharson RG. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost 2010; 8 (10) 2208-2213
    CrossrefPubMedSearch in Google Scholar
  • 46 Page JM, Christiansen-Lindquist L, Thorsten V. , et al. Diagnostic tests for evaluation of stillbirth: results from the stillbirth collaborative research network. Obstet Gynecol 2017; 129 (04) 699-706
    CrossrefPubMedSearch in Google Scholar
  • 47 Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14 (02) 131-136
    PubMedSearch in Google Scholar
  • 48 Högdén A, Antovic A, Berg E, Bremme K, Chaireti R. Obstetric outcomes in patients with primary thrombotic and obstetric antiphospholipid syndrome and its relation to the antiphospholipid antibody profile. Lupus 2019; 28 (07) 868-877
    CrossrefPubMedSearch in Google Scholar
  • 49 Bartsch E, Medcalf KE, Park AL, Ray JG. ; High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 2016; 353: i1753
    CrossrefPubMedSearch in Google Scholar
  • 50 Schlembach D, Stephan H. . Hypertensive Schwangerschaftserkrankungen: Diagnostik und Therapie (Registernummer 015–018). Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften 2019: 1-117 . Available at: https://www.awmf.org/uploads/tx_szleitlinien/015-018l_S2k_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2019-07.pdf . Accessed February 17, 2020
    PubMed
  • 51 Yamada H, Atsumi T, Kobashi G. , et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009; 79 (02) 188-195
    CrossrefPubMedSearch in Google Scholar
  • 52 do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol 2010; 116 (06) 1433-1443
    CrossrefPubMedSearch in Google Scholar
  • 53 Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R. , et al; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 1000 consecutive cases. Autoimmun Rev 2019; 18 (04) 406-414
    CrossrefPubMedSearch in Google Scholar
  • 54 Rodger MA, Langlois NJ, de Vries JI. , et al. Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). Syst Rev 2014; 3: 69
    CrossrefPubMedSearch in Google Scholar
  • 55 van Hoorn ME, Hague WM, van Pampus MG, Bezemer D, de Vries JI. ; FRUIT Investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol 2016; 197: 168-173
    CrossrefPubMedSearch in Google Scholar
  • 56 Saccone G, Berghella V, Maruotti GM. , et al; PREGNANTS (PREGNancy in women with ANTiphospholipid Syndrome) working group. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol 2017; 216 (05) 525.e1-525.e12
    CrossrefPubMedSearch in Google Scholar
  • 57 Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G. , et al. Comparative incidence of pregnancy outcomes in thrombophilia-positive women from the NOH-APS observational study. Blood 2014; 123 (03) 414-421
    CrossrefPubMedSearch in Google Scholar
  • 58 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (05) 1827-1832
    CrossrefPubMedSearch in Google Scholar
  • 59 Gebhart J, Posch F, Koder S. , et al. High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. Blood Adv 2019; 3 (05) 769-776
    CrossrefPubMedSearch in Google Scholar
  • 60 Yelnik CM, Laskin CA, Porter TF. , et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 2016; 3 (01) e000131
    CrossrefPubMedSearch in Google Scholar
  • 61 Stone S, Hunt BJ, Khamashta MA, Bewley SJ, Nelson-Piercy C. Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol. J Thromb Haemost 2005; 3 (02) 243-245
    CrossrefPubMedSearch in Google Scholar
  • 62 Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 2011; 128 (01) 77-85
    CrossrefPubMedSearch in Google Scholar
  • 63 Ruffatti A, Tonello M, Visentin MS. , et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011; 50 (09) 1684-1689
    CrossrefPubMedSearch in Google Scholar
  • 64 Ruffatti A, Calligaro A, Hoxha A. , et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 2010; 62 (03) 302-307
    CrossrefPubMedSearch in Google Scholar
  • 65 Liu L, Sun D. Pregnancy outcomes in patients with primary antiphospholipid syndrome: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98 (20) e15733
    PubMedSearch in Google Scholar
  • 66 Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376 (9751): 1498-1509
    CrossrefPubMedSearch in Google Scholar
  • 67 Hunt BJ, Missfelder-Lobos H, Parra-Cordero M. , et al. Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women undergoing uterine artery Doppler screening at 23 weeks. J Thromb Haemost 2009; 7 (06) 955-961
    CrossrefPubMedSearch in Google Scholar
  • 68 Le Thi Huong D, Wechsler B, Vauthier-Brouzes D. , et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford) 2006; 45 (03) 332-338
    CrossrefPubMedSearch in Google Scholar
  • 69 Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 92-128
    CrossrefPubMedSearch in Google Scholar
  • 70 DGGG DGfGuGeV. Diagnostik und Therapie von Frauen mit wiederholten Spontanaborten (AWMF online). Available at: https://wwwawmforg/leitlinien/detail/ll/015-050html
    PubMed
  • 71 Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011; 117 (25) 6948-6951
    CrossrefPubMedSearch in Google Scholar
  • 72 Andreoli L, Bertsias GK, Agmon-Levin N. , et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76 (03) 476-485
    CrossrefPubMedSearch in Google Scholar
  • 73 Tektonidou MG, Andreoli L, Limper M, Tincani A, Ward MM. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open 2019; 5 (01) e000924
    CrossrefPubMedSearch in Google Scholar
  • 74 Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS One 2010; 5 (10) e13663
    CrossrefPubMedSearch in Google Scholar
  • 75 Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest 2016; 126 (08) 2933-2940
    CrossrefPubMedSearch in Google Scholar
  • 76 Fanouriakis A, Kostopoulou M, Alunno A. , et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78 (06) 736-745
    CrossrefPubMedSearch in Google Scholar
  • 77 Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016; 214 (02) 273.e1-273.e8
    CrossrefPubMedSearch in Google Scholar
  • 78 Mekinian A, Lazzaroni MG, Kuzenko A. , et al; SNFMI and the European Forum on Antiphospholipid Antibodies. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015; 14 (06) 498-502
    CrossrefPubMedSearch in Google Scholar
  • 79 Lazzaroni MG, Fredi M, Andreoli L. , et al. Triple antiphospholipid (aPL) antibodies positivity is associated with pregnancy complications in aPL carriers: a multicenter study on 62 pregnancies. Front Immunol 2019; 10: 1948
    CrossrefPubMedSearch in Google Scholar
  • 80 Sciascia S, Branch DW, Levy RA. , et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost 2016; 115 (02) 285-290
    Thieme ConnectPubMedSearch in Google Scholar
  • 81 Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5 (11) 2060-2068
    CrossrefPubMedSearch in Google Scholar
  • 82 Antovic A, Sennström M, Bremme K, Svenungsson E. Obstetric antiphospholipid syndrome. Lupus Sci Med 2018; 5 (01) e000197
    CrossrefPubMedSearch in Google Scholar
  • 83 Clowse ME, Magder LS, Witter F, Petri M. Early risk factors for pregnancy loss in lupus. Obstet Gynecol 2006; 107 (2, Pt 1): 293-299
    CrossrefPubMedSearch in Google Scholar
  • 84 Mankee A, Petri M, Magder LS. Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss. Lupus Sci Med 2015; 2 (01) e000095
    CrossrefPubMedSearch in Google Scholar
  • 85 Andreoli L, Gerardi MC, Fernandes M. , et al. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmun Rev 2019; 18 (02) 164-176
    CrossrefPubMedSearch in Google Scholar
  • 86 Meroni PL. Prevention & treatment of obstetrical complications in APS: is hydroxychloroquine the Holy Grail we are looking for?. J Autoimmun 2016; 75: 1-5
    CrossrefPubMedSearch in Google Scholar
  • 87 Yelnik CM, Lambert M, Drumez E. , et al. Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. Lupus 2018; 27 (10) 1679-1686
    CrossrefPubMedSearch in Google Scholar
  • 88 Arnaud L, Mathian A, Devilliers H. , et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 2015; 14 (03) 192-200
    CrossrefPubMedSearch in Google Scholar
  • 89 Fanouriakis A, Kostopoulou M, Alunno A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78 (06) 736-745 . doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29
    CrossrefPubMedSearch in Google Scholar
  • 90 Motta M, Chirico G, Rebaioli CB. , et al. Anticardiolipin and anti-beta2 glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Perinatol 2006; 23 (04) 247-251
    Thieme ConnectPubMedSearch in Google Scholar
  • 91 Peixoto MV, de Carvalho JF, Rodrigues CE. Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review. J Immunol Res 2014; 2014: 672603
    PubMedSearch in Google Scholar
  • 92 Nalli C, Iodice A, Andreoli L. , et al. Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome. Lupus 2017; 26 (05) 552-558
    CrossrefPubMedSearch in Google Scholar
  • 93 Groot N, de Graeff N, Avcin T. , et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis 2017; 76 (10) 1637-1641
    CrossrefPubMedSearch in Google Scholar
  • 94 Schreiber K, Sciascia S, de Groot PG. et al. Antiphospholipid syndrome. Nat Rev Dis Primers 2018; (04) 18005 ; Doi: 10.1038/nrdp.2017.103
    PubMedSearch in Google Scholar